ReviewMedComm2026
Lymphatic Endothelial Cells in Health and Disease.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphatic endothelial cells (LECs) line the lymphatic vasculature and support interstitial fluid drainage, lipid transport, and immune-cell trafficking. Beyond these classical functions, recent studies now recognize LECs as heterogeneous, spatially organized endothelial regulators that maintain lymphatic identity while adopting tissue-, segment-, and disease-associated states. Advances in lineage tracing, multiomics, functional imaging, and perturbation studies now link LEC heterogeneity to drainage control, immune surveillance, antigen handling, metabolic homeostasis, and tissue repair. Despite these advances, a unified framework explaining how developmental origin, tissue niche, and context-dependent state transitions collectively shape LEC function across physiology and disease remains lacking. In this review, we summarize the developmental origins, identity-maintenance mechanisms, and anatomical deployment of LEC states across the lymphatic network. We then discuss how specialized LEC states coordinate lymphatic transport, immune surveillance, and peripheral tolerance under homeostasis. We further examine how context-dependent LEC reprogramming contributes to lymphatic disorders, inflammation and autoimmunity, cancer, cardiometabolic disease, and central nervous system dysfunction. Finally, we highlight challenges and opportunities for translational LEC-targeted therapy. Together, this state-centered framework reframes LECs as actionable regulators of tissue homeostasis and disease progression, providing a conceptual foundation for precision lymphatic medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.